CHARLOTTE C SUN to Ovarian Neoplasms
This is a "connection" page, showing publications CHARLOTTE C SUN has written about Ovarian Neoplasms.
Connection Strength
4.248
-
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145.
Score: 0.270
-
Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gynecol Oncol. 2020 12; 159(3):601-603.
Score: 0.236
-
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
Score: 0.183
-
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
Score: 0.164
-
Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
Score: 0.146
-
Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol. 2007 Jan; 4(1):18-29.
Score: 0.091
-
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005 Apr; 13(4):219-27.
Score: 0.078
-
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.
Score: 0.077
-
Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 06; 185:101-107.
Score: 0.074
-
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
Score: 0.073
-
Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer. 2023 05 01; 33(5):749-754.
Score: 0.070
-
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer. 2023 01 03; 33(1):1-9.
Score: 0.069
-
Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Sci Rep. 2022 12 08; 12(1):21269.
Score: 0.069
-
Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis. Ann Surg Oncol. 2023 Mar; 30(3):1508-1519.
Score: 0.068
-
Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002 Oct; 87(1):118-28.
Score: 0.068
-
Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer. 2022 09 06; 32(9):1153-1163.
Score: 0.067
-
Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer. 2022 07 04; 32(7):899-905.
Score: 0.067
-
Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol. 2022 09; 227(3):482.e1-482.e15.
Score: 0.066
-
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.
Score: 0.065
-
Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data. JCO Clin Cancer Inform. 2022 03; 6:e2100187.
Score: 0.065
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.063
-
Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer. 2021 Nov 15; 127(22):4151-4160.
Score: 0.062
-
Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 07; 225(1):68.e1-68.e11.
Score: 0.060
-
Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
Score: 0.060
-
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658.
Score: 0.058
-
National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
Score: 0.058
-
Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725.
Score: 0.056
-
Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol. 2019 08; 154(2):405-410.
Score: 0.054
-
Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
Score: 0.053
-
Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
Score: 0.053
-
Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
Score: 0.051
-
Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
Score: 0.050
-
Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol Oncol. 2018 07; 150(1):79-84.
Score: 0.050
-
Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
Score: 0.049
-
Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
Score: 0.048
-
Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb; 117(2):236-244.
Score: 0.047
-
A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
Score: 0.047
-
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol. 2017 04; 145(1):37-40.
Score: 0.046
-
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
Score: 0.045
-
Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
Score: 0.045
-
Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY). 2016 08; 41(8):1589-95.
Score: 0.044
-
Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. 2016 09; 142(3):525-30.
Score: 0.044
-
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer. 2015 Nov 03; 113(9):1254-8.
Score: 0.042
-
Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015 Aug; 138(2):388-93.
Score: 0.041
-
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015 Jan; 136(1):25-9.
Score: 0.039
-
Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
Score: 0.039
-
Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014 May; 133(2):283-6.
Score: 0.037
-
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
Score: 0.037
-
A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61.
Score: 0.036
-
Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol. 2013 Sep; 130(3):660-6.
Score: 0.035
-
Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
Score: 0.035
-
Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage. 2013 Dec; 46(6):837-45.
Score: 0.035
-
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun; 125(3):661-6.
Score: 0.033
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
Score: 0.032
-
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
Score: 0.032
-
Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011 Aug 15; 117(16):3741-9.
Score: 0.030
-
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
Score: 0.030
-
Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011 Feb; 120(2):229-32.
Score: 0.030
-
Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome. J Cancer Educ. 2010 Sep; 25(3):401-4.
Score: 0.029
-
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
Score: 0.029
-
Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.
Score: 0.029
-
Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010 Feb 01; 28(4):675-82.
Score: 0.028
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.027
-
Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008 Jul 15; 113(2):326-35.
Score: 0.025
-
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
Score: 0.024
-
Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):660-9.
Score: 0.024
-
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
Score: 0.023
-
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May; 105(2):404-8.
Score: 0.023
-
Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am. 2006 Dec; 33(4):621-30, ix.
Score: 0.023
-
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
Score: 0.022
-
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
Score: 0.022
-
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
Score: 0.022
-
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006 Sep; 102(3):468-74.
Score: 0.021
-
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19; 354(3):261-9.
Score: 0.021
-
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74.
Score: 0.020
-
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
Score: 0.019
-
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
Score: 0.018
-
Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics. 2000 Feb; 17(2):133-50.
Score: 0.014
-
Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
Score: 0.010